Adjuvant Chemotherapy Does Not Improve PFS, OS in Locally Advanced Cervical Cancer
Adding adjuvant chemotherapy to standard chemoradiotherapy does not improve outcomes in patients with locally advanced cervical cancer, a phase 3 study suggests.
Adding adjuvant chemotherapy to standard chemoradiotherapy does not improve outcomes in patients with locally advanced cervical cancer, a phase 3 study suggests.
The median price markup was as high as 633.6% for 1 drug.
An elevated C-reactive protein level and an elevated neutrophil-to-lymphocyte ratio were both associated with an increased risk of long COVID.
Overall and progression-free survival were superior with temozolomide.
Roughly half of patients with hematologic cancers or solid tumors lost neutralizing antibody responses to SARS-CoV-2 variants of concern at 6 months after vaccination.
The highest rate of non-concordant care was seen in patients with cervical cancer.
There was no significant difference in disease-free survival, metastasis-free survival, or locoregional recurrence.
A subanalysis of the GOG 252 trial revealed factors associated with longer survival among patients with stage II-III epithelial ovarian cancer.
Response rates improved from 2000 to 2019, but the rate of treatment-related fatal toxicities remained stable.
The response rate observed with mirvetuximab soravtansine was nearly triple the benchmark set in prior studies.